Myoclonic epilepsies are frequently related to mitochondrial disorders, lysosomal disorders and proteinopathic neurodegenerative diseases. Familial cortical myoclonic tremor with epilepsy (FCMTE) is a genetic form of myoclonic epilepsy. FCMTE is defined by an autosomal dominant inheritance, adult onset cortical myoclonic tremor and inconstant seizures. Electrophysiologic examinations show cortical hyperexcitability (paroxysmal polyspike and wave activity on EEG with a marked photosensitivity, recording of enlarged cortical components of somatosensory evoked potential, enhanced long-loop reflex (C-reflex), and cortical transients preceding the myoclonic jerks using the jerk-locked back-averaging technique). Type 3 FCMTE (FAME3/FCMTE3) is linked to the locus 5p15.31-p15.1 [1] . No obvious candidate gene (like ion channel subunit gene for example) is localized to this locus. Actually, no mutation has been found and the biological mechanism involved in FCMTE3 remains unclear. Fronto-striatal dysfunction, gait impairment and cognitive disorders appearing after several decades of disease progression were reported in FCMTE3 [2] .
The patient was a right-handed 52-year-old man with high level of education. No previous personal medical history or neurodevelopmental disorder was reported. A generalized seizure was reported to have occurred at the age of 25, and with a mild bilateral myoclonus in upper limbs beginning at the age of 30 without functional impairment in daily life activities. Migraine without aura and visual intolerance to light and contrast without EEG abnormalities were also reported at the age of 25. Triggering factors were physical exercise, vibration and stress. The patient had been stable for 20 years under valproate (VPA) treatment (1000 mg/day). Genetic linkage to 5p15.31-p15 (FCMTE3) was found. The patient (IV-6) and his pedigree have previously been described in detail [1] . He was therefore considered as a ''paucisymptomatic'' type 3 familial cortical myoclonic tremor with epilepsy (FCMTE3). Written informed consent was obtained from the patient. The study received approval from the ethical standards committee on human experimentation.
At the age of 50, the patient complained of language disorders. Since the disease onset, the myoclonus was stable and mild and the epilepsy was well controlled, with only 3 episodes in 25 years. Neuropsychological evaluation showed cognitive disorders with a logopenic syndrome (anomia, lexical access disorders, reduced spontaneous fluency, and length-dependent deficit) and a verbal short term memory impairment (Table 1) . No Parkinsonism, gait disorder or visuospatial disorders was observed. No other neurological abnormalities were observed. No loss of autonomy was reported.
VPA level was within therapeutic values (62 mg/mL, accepted range 50-100). Amoniemia level was normal. No disorders related to mitochondriopathy or lysosomial disorders (like diabetes, hearing loss, neuropathy, leukoencephalopathy, myocardiopathy, retinopathy, myopathy, nephropathy, hepatopathy, lactic acidosis) were found.
Neuroimaging examinations showed diffuse cortical and basal abnormalities (Fig. 1) . MRI showed diffuse bilateral frontoparietal, mesencephalic, cerebellar and left hippocampic atrophy without white matter hyperintensity. Brain perfusion SPECT (99mTc-HMPAO) showed predominantly left-sided bilateral fronto-parieto-occipital hypoperfusion. DAT-SPECT showed loss of dopamine transporter (DAT) in the left striatum (mean striatal-occipital ratio was 0.91 on left side vs 1.32 on the right side, N > 1.2).
Electroencephalogram follow-up showed no abnormality. A progressive switch from VPA to levetiracetam was proposed. However, he declined because the decrease in VPA had led to a severe increase in his father's myoclonus (III-10) [2] .
Our case underpins the frontostriatal abnormalities that have been reported in severe form of FCMTE3 during aging. Those abnormalities could explain cognitive and visual symptoms. In addition to frontal lobe dysfunction previously described, a left posterior cortical dysfunction was also observed and can explain the logopenic syndrome [3] . Occipitoparietal and basal abnormalities can participate in the visual intolerance to the light and contrast as well [2] .
These abnormalities were initially considered to be consequences of chronic myoclonus. However, a primitive etiological mechanism of FCMTE is not excluded [2] . In our patient and the two cases previously described, the predominantly left-sided dysfunction suggests a lateralized tropism of FCMTE3. As the myoclonus was not predominant in the right side, these results support a primitive neurodegenerative dysfunction in FCMTE3. In the previous study, both FCMTE3 patients presented severe myoclonus and were over 65 when gait disorders and major cognitive decline occurred [2] . Our observation shows that corticobasal abnormalities can occur in a younger FCMTE3 patient (52 year old) with very mild myoclonus and infrequent seizures. Those results suggest that corticobasal abnormalities are independent of severity of myoclonus and epilepsy. Moreover, none of the sixteen FMCTE3 patients present cognitive neurodevelopmental disorder [2] and our had a high level of education and no neurodevelopmental linguistic disorders. Therefore, age might have play a role in the occurrence of cognitive disorders and corticobasal dysfunctions. Our results suggest that those symptoms can possibly begin around fifty year old by a mild cognitive impairment and sometimes can evolve into a major cognitive impairment with severe myoclonus and gait disorders around sixty year old.
From a pathogenic point of view, a mutation of aminocarboxymuconate semialdehyde decarboxylase gene (ACMSD), an enzyme that might be involved in dopaminergic metabolism, was found in another type 2 FCMTE family: it supports a possible primitive dopaminergic dysfunction in this syndrome [4] , as does the DATscan results of our patients.
Here, another possible explanation is an iatrogenic origin induced by chronic VPA treatment. VPA may induce Parkinsonism and cognitive impairment. However, encephalopathy due to VPA would have result in confusion with a diffuse, fluctuating cognitive impairment, diminished level of consciousness, EEG abnormalities, and hyperammonemia. Besides, the patient had taken VPA treatments for two decades. There is no specific study about the influence of chronic VPA treatment on DAT-SPECT, and the effect of chronic VPA treatment in the dopaminergic system remains unclear: toxicity on dopaminergic neurons, a neuroprotective effect or an increase in dopamine transporter gene expression [2] . However, an iatrogenic origin would have result in a symmetric cerebral toxicity.
In conclusion, FCMTE3 might have a neurodegenerative evolution during aging independent of the severity of epilepsy and myoclonus. Clinical and imaging findings raise hypotheses about the physiopathology of this evolution. Both dopaminergic and cortical dysfunctions may explain the phenotypic characteristics of this patient. Further functional, neuropathological, and genetic analyses with a systematic follow-up are needed to better understand the physiopathology and the timing of these dysfunctions.
